Trung Huynh
Stock Analyst at UBS
(3.09)
# 404
Out of 4,667 analysts
30
Total ratings
43.75%
Success rate
4.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $4.12 | +215.53% | 1 | Oct 10, 2024 | |
| CABA Cabaletta Bio | Initiates: Buy | $10 | $2.26 | +342.48% | 1 | Oct 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $54 | $58.07 | -7.01% | 4 | Oct 9, 2024 | |
| INSM Insmed | Maintains: Buy | $78 → $84 | $72.67 | +15.59% | 3 | Aug 9, 2024 | |
| LLY Eli Lilly | Assumes: Buy | $612 → $710 | $742.30 | -4.35% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $153.25 | +14.19% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $287.87 | -30.52% | 3 | Jul 12, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $47 → $40 | $24.83 | +61.08% | 4 | Jun 29, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $125 → $126 | $97.40 | +29.37% | 3 | Mar 7, 2023 | |
| ABBV AbbVie | Initiates: Outperform | $170 | $167.76 | +1.34% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.60 | - | 1 | Mar 23, 2021 |
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $4.12
Upside: +215.53%
Cabaletta Bio
Oct 10, 2024
Initiates: Buy
Price Target: $10
Current: $2.26
Upside: +342.48%
Bristol-Myers Squibb Company
Oct 9, 2024
Maintains: Neutral
Price Target: $50 → $54
Current: $58.07
Upside: -7.01%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $78 → $84
Current: $72.67
Upside: +15.59%
Eli Lilly
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $742.30
Upside: -4.35%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $153.25
Upside: +14.19%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $287.87
Upside: -30.52%
Pfizer
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $24.83
Upside: +61.08%
Merck & Co.
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $97.40
Upside: +29.37%
AbbVie
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $167.76
Upside: +1.34%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.60
Upside: -